Unlock instant, AI-driven research and patent intelligence for your innovation.

Synthesis method of N-1 crystal form Apixaban

A synthesis method, the technology of apixaban, applied in the field of synthesis of apixaban, achieves the effects of mild process conditions, reduced discharge of a large amount of nitrogen-containing wastewater, and easy subsequent treatment and recovery

Active Publication Date: 2018-04-20
ZHEJIANG TIANYU PHARMA
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] The present invention provides a new synthesis method of apixaban in the N-1 crystal form, which uses dichloromethane as a solvent, and solves the problem of producing a large amount of nitrogen-containing waste water caused by using DMF in the existing synthesis method

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Synthesis method of N-1 crystal form Apixaban
  • Synthesis method of N-1 crystal form Apixaban
  • Synthesis method of N-1 crystal form Apixaban

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Embodiment 1: Preparation of Apixaban

[0040] At room temperature, add 4.88g of intermediate 1, 4.5g of formamide, 0.14g of tetrabutylammonium chloride, and 50mL of dichloromethane into a 250mL three-necked flask, stir, and cool in an ice bath to 0-5°C. Add 5.4g of sodium methoxide, after dropping, keep the temperature at 0-5°C and stir for 30min, then remove the ice bath and naturally rise to 20-25°C, react for 4h, TLC monitors the disappearance of intermediate 1, add 100ml of water to the synthesis solution, stir After half an hour, the reaction solution was allowed to stand for layers. The dichloromethane layer was separated and the dichloromethane was concentrated to dryness. The residue was vacuum-dried to obtain 4.50 g of a light yellow solid with a yield of 97.8% and a purity of 98.35%.

[0041] Add 135 mL of methanol solution of acetic acid with a mass fraction of 6% to 4.50 g of the crude apixaban obtained above, heat to reflux to dissolve, then stir and natur...

Embodiment 2

[0046] Embodiment 2: Preparation of Apixaban

[0047] At room temperature, add 4.88g of intermediate 1, 4.5g of formamide, 0.16g of tetrabutylammonium bromide, and 50mL of dichloromethane into a 250mL three-neck flask, stir, and cool in an ice bath to 0-5°C. Add 5.4g of sodium methoxide, after dropping, keep the temperature at 0-5°C and stir for 30min, then remove the ice bath and naturally rise to 20-25°C, react for 4h, TLC monitors the disappearance of intermediate 1, add 100ml of water to the synthesis solution, stir After half an hour, the reaction solution was allowed to stand for layers. The dichloromethane layer was separated and the dichloromethane was concentrated to dryness. The residue was vacuum-dried to obtain 4.35 g of a light yellow solid with a yield of 94.5% and a purity of 98.21%.

[0048] Add 130 mL of methanol solution of acetic acid with a mass fraction of 6% to 4.35 g of the crude apixaban obtained above, heat to reflux to dissolve, then stir and naturall...

Embodiment 3

[0053] Embodiment 3: Preparation of Apixaban

[0054] At room temperature, add 4.88g of intermediate 1, 4.5g of formamide, 0.11g of benzyltriethylammonium chloride, and 50mL of dichloromethane into a 250mL three-necked flask, stir, and cool in an ice bath to 0-5°C. Slowly add 5.4g of sodium methoxide to the mixture, after dropping, keep the temperature at 0-5°C and stir for 30min, then remove the ice bath and naturally rise to 20-25°C, react for 4h, TLC monitors that intermediate 1 disappears, add 100ml of water to the synthesis solution , stirred for half an hour, the reaction solution was left to stand and separated, the dichloromethane layer was separated and the dichloromethane was concentrated to dryness, and the residue was vacuum-dried to obtain 4.40 g of a light yellow solid, yield: 95.6%, purity 98.43%.

[0055] Add 132 mL of methanol solution of acetic acid with a mass fraction of 6% to 4.40 g of the crude apixaban obtained above, heat to reflux to dissolve, then sti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention provides a synthesis method of N-1 crystal form Apixaban. The synthesis method of the N-1 crystal form Apixaban is characterized by comprising the following steps: mixing an intermediate1, formamide, a phase transfer catalyst and dichloromethane, adding sodium methoxide into the mixture, performing reaction, separating after reaction to obtain an Apixaban crude product, and recrystallizing the crude product to obtain the N-1 crystal form Apixaban. According to the method, the dichloromethane serves as a solvent, so that discharge of a large amount of nitrogen-containing wastewater brought by DMF is effectively reduced; furthermore, the dichloromethane is easy to subsequently treat and recover, the whole process is mild in process condition and the method is suitable for industrialized production. (The formula is as shown in the description).

Description

technical field [0001] The invention relates to the field of medicine and chemical industry, in particular to a method for synthesizing N-1 crystal form apixaban. Background technique [0002] Apixaban, its English name is Apixaban (trade name: Eliquis), its chemical name is 4,5,6,7-tetrahydro-1-(4-methoxyphenyl)-7-oxo-6 -[4-(2-oxo-1-piperidinyl)phenyl]-1H-pyrazolo[3,4-c]pyridine-3-carboxamide, CAS: 503612-47-3, its chemical structure as follows: [0003] [0004] Apixaban is a new generation of antithrombotic drugs. It is a new type of direct factor Xa inhibitor jointly developed by Bristol-Myers Squibb and Pfizer. It was approved for marketing in the European Union in March 2011 and launched in 2012 In December, the FDA approved the drug to be launched in the United States. At present, this product is clinically used to prevent venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement. Among many coagulation factor Xa inhibitors, apix...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D471/04
CPCC07B2200/13C07D471/04
Inventor 柯春龙朱国荣李美君屠勇军
Owner ZHEJIANG TIANYU PHARMA